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Dyslipidemia Associated
with Atherosclerotic Disease
Systemically Alters Dendritic Cell Mobilization
kines that induce the recruitment of monocytes (Ross,
1993). Uptake of these modified lipoproteins by differ-
entiating monocytes leads to the formation of the le-
sions.
Oxidation of LDL also generates a variety of immuno-
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teins. These neoepitopes elicit autoimmune responses asProgram and
demonstrated by the detection of autoantibodies reactingThe New York University Lipid Treatment
with oxidized LDL, but not native LDL, in plasma (Orekhovand Research Center
et al., 1991; Palinski et al., 1994). Oxidation of phosphati-New York University
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plification of the titers of this antibody decreases theJapan
progression of atherosclerosis by neutralizing and pos-
sibly promoting the clearance of oxidized LDL, instead
of being pathogenic (Binder et al., 2003; Palinski etSummary
al., 1995).
Autoantibodies recognizing oxidized LDL are not onlyHigh LDL and/or low HDL are risk factors for athero-
found in atherosclerosis but also in several autoimmunesclerosis and are also a common clinical feature in
disorders like systemic lupus erythematosus (SLE), pso-systemic lupus erythematosus, rheumatoid arthritis,
riasis, and rheumatoid arthritis (RA) (Amara et al., 1995;and psoriasis. Here, we show that changes in lipid
Cvetkovic et al., 2002; Hayem et al., 2001; Orem et al.,profiles that reflect atherosclerotic disease led to acti-
1999; Wu et al., 1999). Elevated titers of these antibodiesvation of skin murine dendritic cells (DCs) locally, pro-
in SLE, psoriasis, and RA coincides with increased levelsmoted dermal inflammation, and induced lymph node
of very low-density lipoprotein, LDL, or oxidized LDLhypertrophy. Paradoxically, DC migration to lymph
and correspondingly decreased levels of high-densitynodes was impaired, suppressing immunologic prim-
lipoprotein (HDL) and apolipoprotein A-I (ApoA-I), theing. Impaired migration resulted from inhibitory sig-
major apoprotein in HDL (Burger and Dayer, 2002; Ilo-nals generated by platelet-activating factor (PAF) or
wite et al., 1988; Tselepis et al., 1999). Despite clinicaloxidized LDL that acts as a PAF mimetic. Normal DC
data linking dyslipidemia to autoimmune disorders, ba-migration and priming was restored by HDL or HDL-
sic research to address how dyslipidemia itself mayassociated PAF acetylhydrolase (PAFAH), which medi-
affect the immune system has just recently begun to
ates inactivation of PAF and oxidized LDL. Thus, ath-
receive attention (Aprahamian et al., 2004).
erosclerotic changes can sequester activated DCs in Here, we explored how dendritic cell (DC) function is
the periphery where they may aggravate local inflam- affected by dyslipidemia that occurs in mice lacking
mation even as they poorly carry out functions that apolipoprotein E (ApoE) or LDL receptor. We probed DC
require their migration to lymph nodes. In this context, functions in the skin and draining lymph nodes (LNs),
HDL and PAFAH maintain a normally functional DC since the skin is a major target organ in many autoim-
compartment. mune diseases. The study reveals an initial period of
spontaneous activation of skin DCs during early weeks
Introduction of dyslipidemia, followed by a subsequent strong de-
pression of mobilization to LNs, which leads, at this
Atherosclerosis is a chronic inflammatory disease of the stage, to poor immunologic priming. We further uncover
arterial vasculature (Libby, 2002), and the possibility that a critical role for HDL and its associated enzyme PAF
atherosclerosis is an autoimmune disease has been dis- acetylhydrolase (PAFAH) in maintaining normal DC mi-
cussed (Palinski and Witztum, 2000; Wick et al., 2004). gration and immunization.
Early lesions of atherosclerosis result from the subendo-
thelial accumulation of low-density lipoprotein (LDL) that Results
when trapped in the vessel wall undergoes modifica-
tions, particularly oxidation. Oxidized LDL triggers the Systemic Age-Dependent and Diet-Accelerated
production of proinflammatory cytokines and chemo- Hypertrophy of LNs in Apoe/ Mice
A diet rich in fat and cholesterol (Western diet) acceler-
ates disease in Apoe/mice, but the strain develops*Correspondence: gwendalyn.randolph@mssm.edu
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Figure 1. Perturbations in LNs and Skin of Apoe/ Mice
Wt and Apoe/ mice were studied at 6, 16, and 34 weeks of age. Some were placed on a Western diet at 6 week of age.
(A) Relative number of cells in skin-draining LNs was determined in order to combine values from the four experiments conducted (n  4).
By 16 weeks and thereafter, the values between wt and atherosclerotic mice were significantly different; p  0.05 independent of diet type.
(B) Epidermal sheets from wt and Apoe/ mice were stained with anti-IAb mAb. Low power (top two rows) and high power (last two rows)
magnifications are shown. For analysis of MHC class II distribution, epidermal sheets were stained with anti-IAb mAb (red) and DAPI (blue).
(C) The number of LC/mm2 was evaluated (upper panel). Values between wt and atherosclerotic mice were significantly different, p  1 
105. The number of LCs per LN was calculated by multiplying the percentage of langerin-positive cells by the number of total LN cells
(bottom). Data are combined from three experiments (n  3). Significant differences from wt controls are designated by *p  0.05.
(D) Ear skin sections were stained for histologic analysis (top rows) or with anti-CD68 mAb (bottom row). All scale bars, 40 m.
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disease at a slower rate when fed a standard chow diet monocytes, macrophages, and some stages of DC mat-
uration.(Breslow, 1996). A time course that charted the effects
of age and the Western diet revealed that Apoe/ lymph
nodes (LNs) systemically became hypertrophic with age. Skin DC Migration in Apoe/ Mice Is Impaired
This increase in LN cellularity was accelerated by feed- by 16 Weeks of Age
ing with a Western diet, such that LN hypertrophy was Signs of activated LCs, dermal infiltration, and hypertro-
evident by 16 weeks of age in Apoe/ mice fed a West- phic skin-draining LNs are consistent with the notion of
ern diet but was not evident until 34 weeks of age in immune activation in atherosclerosis. We hypothesized
chow-fed Apoe/ animals (Figure 1A). that the inflammatory environment in atherosclerotic
mice activated skin DCs and promoted their mobilization
Loss of Skin DC Homeostasis Precedes to LNs, which in turn might facilitate subsequent LN
the Onset of LN Hypertrophy hypertrophy. We thus studied DC migration by using a
Systemic effects, such as skin inflammation, have been model based on the topical application of FITC in a
described in atherosclerotic mice (Feingold et al., 1995; contact-sensitizing solution that results in the appear-
van Ree et al., 1995). Considering the observed LN hy- ance of FITC skin-derived DCs in the draining LNs.
pertrophy and the known skin inflammation, we focused Compared to wt mice, 16 week-old Apoe/ mice
on the possibility that skin DC were affected. Apoe/ showed a significant decrease in the accumulation of
mice that were 6 weeks of age and maintained on a FITC DCs in LNs independent of diet type (Figures
chow diet showed a uniform network of MHC II DCs 2A–2C). Wt mice fed a Western diet showed no differ-
in the epidermis at similar density as observed in wt ences in DC migration relative to chow-fed counterparts
mice (Figures 1B and 1C, top). However, at this relatively (data not shown).
early age, the total number of Langerin epidermal DCs These results were expressed as the percentage of
(Langerhans cells, LCs) in skin draining LNs was in- FITC DCs in the LNs (Figure 2B) or as the number of
creased in Apoe/ mice at 6 weeks of age, suggesting FITC DCs in the LNs (Figure 2C). Both methods
that LCs may be emigrating to LNs at a greater rate in of calculation revealed that DC migration was inhibited
Apoe/ mice than in wt mice at this age (Figure 1C, in Apoe/ mice fed a chow diet or a Western diet com-
bottom). Consistent with this possibility, there were 50% pared to wt mice. Because wt DCs migrate in greater
fewer LCs per mm2 in Apoe/ mice fed either a chow numbers to larger LNs and indeed migrate into LNs in
or a Western diet by 16 weeks, when the disease is well proportion to LN size (Supplemental Figure S1 available
underway (Breslow, 1996) (Figures 1B and 1C, top). This online at http://www.immunity.com/cgi/content/full/21/
loss reached a plateau such that later times examined 4/561/DC1/), normal DC migration is best appreciated
were similar to 16 weeks. The ears of 34-week-old as the percentage of FITC DCs. Thus, in many of the
Apoe/ mice fed a Western diet were too irritated and remaining experiments DC migration was expressed as
damaged to perform analysis. At and after 16 weeks the percentage of FITC DCs to eliminate independent
of age, the number of LCs in the LN was decreased variance due to differences in LN size/cellularity.
compared to wt mice (Figure 1C, bottom). Furthermore, Examination of the epidermis from 16- and 34-week-
by 16 weeks, independent of diet type, DCs that re- old Apoe/ mice fed a chow or a Western diet revealed
mained in the epidermis appeared activated compared a decreased percentage of LCs that migrated from the
to LCs from wt epidermis. Deconvolution imaging indi- epidermis after FITC sensitization compared to an aver-
cated that they expressed MHC II on the surface instead age loss of 35%–40% (150–200 cells/mm2) in wt controls
of in an intracellular perinuclear compartment, as usually (Figure 2D). The possibility that the loss of DCs from the
seen in vivo (color panels, Figure 1B). epidermis and even the failure of DCs to migrate to the
The age-dependent reduction in epidermal DCs in LNs when probed at 16 or 34 weeks of age was related
atherosclerotic mice suggests that developmental seed- to the baseline reduction in epidermal DC density is
ing of the epidermis with DCs was normal; that between unlikely because the migration of DCs after FITC appli-
6 and 16 weeks of age, and therefore prior to LN hyper- cation is not affected in other strains of mice, such as
trophy, events in the skin caused some LCs to leave the CD40L transgenic mice (Mehling et al., 2001) or op/op
epidermis and accumulate in LNs; and that the turnover mice (Randolph et al., 1998a), which show a substantially
of LCs was insufficient to meet demand for replacement. reduced density of epidermal DCs (Witmer-Pack et al.,
1993). Furthermore, as shown below, DC migration can
be fully restored under conditions when DC density inAlterations in the Dermis of Apoe/ Mice
We also observed a generalized increase in baseline ear the epidermis changes only minimally.
Inhibition of DC migration in atherosclerotic mice wasthickness in Apoe/ mice compared with wt counter-
parts. Histopathological analysis of ear sections from also not explained by decreased expression of CCR7.
Indeed, CCR7 mRNA was induced after FITC paintingApoe/ mice and matched controls revealed no differ-
ences compared to wt at 6 weeks of age (Figure 1D). in wt mice at 6 and 16 weeks of age, and similar levels
of CCR7 were detected in the epidermis of Apoe/ miceWith time, Apoe/ skin was affected by hyperkeratosis,
spongiosis, and dermal accumulation of lymphohistio- when the mice developed disease (at 16 weeks of age)
(Figure 2E). CCR7 expression was not altered (induced)cytic cells (Figure 1D) consistent with a previous study
(van Ree et al., 1995). These cells colocalized with scat- in the steady-state epidermis of Apoe/ mice, even
when signs of inflammation and DC activation weretered CD4 cells and a few cells bearing LC markers like
langerin (not shown). There were also notably increased present.
Finally, we confirmed that the decreased number ofnumbers of CD68 cells (Figure 1D) that would identify
Immunity
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Figure 2. Analysis of DC Migration to Draining LNs in Apoe/ Mice
(A) Wt and Apoe/mice received epicutaneous FITC, and the accumulation of FITC cells (x axis) in the LNs was assessed. DCs were identified
by using PE-conjugated anti-CD11c mAb (y axis).
(B) Percentage of FITCCD11c DCs in LNs from wt and Apoe/ mice was determined (means of four experiments).
(C) To combine values from four independent experiments, the relative number of FITCCD11c DCs per LN for each data point in each
experiment was calculated.
(D) Epidermal sheets from wt and Apoe/ mice fed a chow or a Western diet were stained with anti-IAb mAb after one ear was painted with
FITC. Percentage of migrated LCs was calculated by comparing densities between painted and unpainted ears. Data are from four experiments.
(E) CCR7 mRNA expression in emigrated LCs from wt and Apoe/ epidermis was assessed in the steady state and 18 hr after FITC painting.
(F) Epidermal suspension were prepared 18 hr after FITC application and stained with CD45. Gated CD45 cells were analyzed for FITC
content. Significant differences from wt controls are designated by *p  0.05.
Dyslipidemia and DC Migration
565
more, shifts in DC density in the epidermis (Figure 3B)
and LN cellularity (Figure 3C) were not observed in
Apoe//hApoA-I/ mice, in contrast to Apoe/ mice.
These data suggest that elevating HDL from birth
quells the onset of alterations in skin DCs and LN hyper-
trophy. However, studies in these transgenic mice are
inherently unable to delineate whether HDL could re-
verse the observed alterations in DC function and LN
hypertrophy once established. To begin to address this
question, wt and Apoe/ mice were treated intrave-
nously (i.v.) with 500g HDL isolated from normal human
plasma every day for 7 days. On the last day of treat-
ment, the skin of these mice was painted with FITC, and
the extent to which FITCCD11c DCs accumulated in
the LNs was determined. In wt mice, treatment with HDL
had no effect on the accumulation of FITC DCs in the
LNs compared to mice receiving only PBS (Figure 3D). In
contrast, HDL injection in Apoe/ mice partially restored
migration of FITC DCs to LNs, increasing the fraction
of FITCCD11c DCs in draining LNs compared to non-
treated Apoe/ mice by 50%. This correction by HDL
was related to a slight decrease in total cholesterol and
increase in HDL-cholesterol in plasma from Apoe/
mice compared to untreated Apoe/ mice (Table 1). The
transfer of HDL to wt mice did not affect their plasma
Figure 3. Effect of Elevating HDL on DC Migration in Apoe/ Mice lipid profiles (Table 1). Thus, short-term treatment with
(A) The accumulation of FITC DCs in LNs after FITC painting, (B) HDL partially reverses the impaired DC mobilization to
the baseline LC density, and (C) LN cellularity were evaluated in LNs that is blocked in Apoe/ mice.
wt, Apoe/, and Apoe//hApoA-I/ mice fed a Western diet for
10 weeks.
PAFAH Is a Component of HDL Required(D) Wt and Apoe/ mice fed a Western diet for 10 weeks received
to Maintain Normal DC Migrationi.v. 500 g of human albumin (control) or HDL isolated from normal
plasma (HDL) for 7 days before FITC application. One typical experi- HDL is enriched in proteins that scavenge oxidized mol-
ment is shown for each part of the figure. Each experiment was ecules, including in particular PAFAH (Marathe et al.,
repeated three times with similar results. Significant differences from 2003). Plasma PAFAH activity is critical for the inactiva-
untreated Apoe/ controls are shown; *p  0.001. tion of PAF and PAF-like lipids associated with oxidized
LDL (Forte et al., 2002), and gene therapy approaches
that raise the level of PAFAH decrease the progressionFITC DCs in LN from Apoe/ mice did not result from
impaired FITC uptake by skin DCs (Figure 2F). Indeed, of atherosclerosis (Quarck et al., 2001). Since we have
noticed a migration inhibitory effect on DCs by PAFthe intensity of FITC expression on gated CD45 epider-
mal cells was not different between wt and Apoe/ mice. signals in other models (Llodra et al., 2004), we won-
dered whether the PAFAH endogenously associatedAltogether, these data illustrate that DC migration to
LNs is impaired in Apoe/ mice by 16 weeks of age, a with HDL accounted for the migration restorative effect
of HDL. First, wt and Apoe/ mice maintained on atime when progression of atherosclerosis is well under-
way in both chow and Western diet-fed animals (Bres- Western diet for 12 weeks received i.v. for 7 consecutive
days 500 g HDL isolated from plasma from a normallow, 1996), but not in younger 6-week-old mice that have
minimal manifestations of disease. This inhibitory effect donor or from individuals bearing an inactivating muta-
tion in the PAFAH gene (Stafforini et al., 1996). An analy-of DC migration was associated with atherosclerotic
disease in other murine models of atherosclerosis, since sis of PAFAH activity confirmed that this HDL was defi-
cient in PAFAH activity (Figure 4A). In wt mice, treatmentwe observed similar results in Ldlr/ mice (Supplemen-
tal Figure S2). with HDL containing active or mutated PAFAH had no
effect on FITC DC accumulation in the draining LNs
(data not shown). In contrast, in Apoe/ mice, HDL con-HDL Prevents Alterations in DC
Elevating HDL-cholesterol levels can reverse progres- taining active PAFAH partially restored DC migration
and did so much more effectively than HDL lacking func-sion of atherosclerotic disease (Rong et al., 2001). We
wondered if raising HDL might reverse changes ob- tional PAFAH (Figure 4B).
In further experiments, HDL isolated from normal hu-served for skin DCs. Therefore, we evaluated DC migra-
tion in Apoe/ mice that transgenically express human man plasma was treated with an irreversible serine pro-
tease inhibitor, Pefabloc (Dentan et al., 1996), whichApoAI (Apoe//hApoA-I/), the major apoprotein of
HDL. Expression of this transgene leads to elevated reduced PAFAH activity associated with HDL by 85%
(Figure 4A). Then, wt and Apoe/ mice fed a WesternHDL levels (Plump et al., 1994; Schultz et al., 1993). In
Apoe//hApoA-I/ mice, DC migration was not equiva- diet were treated i.v. with 500 g HDL containing active
or biochemically inactivated PAFAH for 7 consecutivelent to wt mice but was significantly improved over
Apoe/ mice lacking this transgene (Figure 3A). Further- days. Again, the modulation of PAFAH activity in this
Immunity
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Table 1. Effect of HDL Treatment on Blood Lipid Profiles
Treatment Total Cholesterol (mg/dl) HDL Cholesterol (mg/dl)
Wild-type None 116.5  31.8 54  4.24
HDL 94  4.2 43.5  10.6
Apoe/ None 1896  46.66* 29.5  2.12
HDL 1528  210.3* 63.3  18
Values are mean  SD. *p  0.1. All mice were fed a Western diet for 12 weeks.
manner had no effect on DC migration in wt mice (data in Apoe/ mice (Figure 4C). In contrast, accumulation
of FITC DCs in LNs was only modestly increased overnot shown). Treatment with HDL containing active
PAFAH reversed the inhibitory effect on DC migration untreated Apoe/ mice when Apoe/ mice received
Figure 4. Role of HDL-Associated PAFAH in
DC Migration
(A) PAFAH activity was measured in HDL iso-
lated from normal plasma (normal), in HDL
derived from individuals who are homozy-
gous deficient for PAFAH (PAFAH/), or in
HDL from normal plasma treated with the Pef-
abloc (Pefabloc).
(B) The effect of normal HDL (Normal), PAFAH-
deficient HDL (PAFAH/), or (C) Pefabloc-
inactivated PAFAH HDL (Pefabloc) treatment
on DC migration was analyzed in Apoe/
mice fed a Western diet after FITC painting.
The results are expressed as the percentage
of migration restored, where 100% reversal
is defined as the difference between the per-
centage of FITC DC in untreated wt and
Apoe/ mice.
(D) Wt or Apoe/ mice kept on the Western
diet received 0.1 mg/kg i.v. of placebo (Pla-
cebo) or recombinant PAFAH (PAFAH) for 7
consecutive days before FITC painting.
(E) Wt and Apoe/ mice kept on the Western
diet for 10 weeks were treated with normal
HDL (Normal), Pefabloc-inactivated PAFAH
HDL (Pefabloc), or recombinant PAFAH (PA-
FAH). Baseline LC density was determined
by immunostaining with anti-IAb mAb.
(F) Total cells numbers in skin draining LNs
were evaluated. Data are combined from
three experiments. Significant differences are
designated by *p  0.05.
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HDL containing inactivated PAFAH (Figure 4C). These erosclerotic disease by oxidation of LDL or generated
in the course of inflammation in skin may negativelyresults indicate that the restoration of DC migration me-
diated by HDL in large part depends on its PAFAH ac- regulate skin DC migration through PAF receptor
(PAFR). This receptor is expressed by human DCs (Dich-tivity.
We next investigated whether administration of re- mann et al., 2000; Sozzani et al., 1997). We detected
PAFR mRNA in mouse LCs that emigrated from culturedcombinant PAFAH for 7 consecutive days would restore
DC migration in Apoe/ mice. Indeed, the fraction of skin explants and in bone marrow-derived DCs (BMDCs)
from wt mice (Figure 6A). Thus, we investigated DCmigrating DCs in the draining LNs from Apoe/ mice
treated with recombinant PAFAH was almost totally re- migration in Pafr/ mice (Ishii et al., 1998; Ishii and
Shimizu, 2000). After FITC application, the fraction andstored to wt levels (Figure 4D).
We wondered whether this treatment might also have the total number of FITCCD11c DCs in Pafr/ mice
LNs were essentially doubled compared with wt (Figuresome impact on LC density that is altered in Apoe/
mice (Figure 1). Compared to untreated Apoe/ mice, 6B). This enhanced migration was associated with a loss
of skin DCs, but the baseline density of LCs in Pafr/the number of LC/mm2 began to show increases toward
wt density after both HDL and PAFAH treatments (Figure mice was similar to wt mice (data not shown). Interfering
in vivo with PAFR by using the specific antagonist4E). There were also slight reductions in the cellularity
of the LNs (Figure 4F). Since PAFAH treatment fully re- CV3988 also increased DC migration in wt mice, but
less substantially than the increases observed in PAFR-stored DC migration but only modestly affected epider-
mal DC density and LN cellularity during 7 days, the deficient mice (Figure 6C). These data support the idea
that PAF signals normally negatively regulate DC migra-data indicate that correcting to normal the impaired DC
migration is not dependent on full correction of the tion in vivo, even curtailing migration in Apoe/ mice
subjected to an activation stimulus.other alterations.
To test whether PAF signals act directly on DCs to
modulate their migration, we adoptively transfered wtHDL-Associated PAFAH Maintains Normal
or Pafr/ CD45.2 BMDCs to wt congenic CD45.1 recipi-Immune Responses
ents, or conversely, BMDCs from wt congenic CD45.1The development of immune responses is severely com-
mice were transferred to wt or Pafr/ recipients. Migra-promised in Apoe/ mice (de Bont et al., 1999; Lasko-
tion of DCs to skin draining LNs was analyzed two dayswitz et al., 2000; Ludewig et al., 2001). Reversing the
later. DC migration to recipient LNs was twice greaterinhibitory effect on DC migration observed in Apoe/
for Pafr/ BMDCs compared with wt BMDCs (Figuremice might have some direct consequences on the ca-
6D). In contrast, the migration of wt BMDCs was notpacity of these mice to elicit immune responses since
different between wt and Pafr/ recipients (Figure 6D).migration of DC from the site of antigen entry to the
Thus, signals through PAFR expressed by DCs them-draining LN is required to induce immune responses like
selves can serve to negatively regulate mobilization fromcontact hypersensitivity (CHS) and delayed-type hyper-
skin to LNs.sensitivity (DTH) (Flores-Romo, 2001).
These observations in mice appear to be relevant toWe first confirmed that CHS and DTH elicited with
human skin DCs. First, human LCs that emigrated fromFITC and OVA, respectively, were depressed in Apoe/
skin explants also expressed PAFR mRNA and fluxedmice at 16 weeks of age (Western diet for 10 weeks).
calcium in response to cPAF (Figure 6E), a specificApoe/ mice mounted greatly reduced CHS and DTH
stable agonist of the PAFR (O’Flaherty et al., 1987). Fur-responses (70% and 50% inhibition, respectively) com-
thermore, the addition of the PAFR antagonist CV3988pared with sensitized wt mice (Figures 5A and 5B).
enhanced LC emigration from skin explants, as muchApoe/ mice treated with either HDL from normal hu-
as IL-1	 (Figure 6E). Treatment with CV3988 affectedman serum or recombinant PAFAH mounted a stronger
neither CCR7 nor costimulatory molecule expression onCHS response compared with untreated Apoe/ mice
LCs (data not shown).that was near to wt levels (Figure 5A), but administration
of PAFAH-inactivated HDL in Apoe/ mice had no bene-
ficial effect on the CHS response. Similarly, restoration Discussion
of DC migration by recombinant PAFAH in Apoe/ mice
improved the DTH responses induced by OVA in these Here, we show that the dyslipidemia associated with
mice (Figure 5B). The expression of costimulatory mole- atherosclerosis markedly modifies DC functions in skin.
cules on LN DCs from Apoe/ mice was similar to wt The presence and migration of DCs in skin are normal
DCs (Figure 5C). DCs were not fully mature in the ab- up through 6 weeks of age. Therefore, the absence of
sence of FITC painting. After FITC painting, the fewer Apoe per se does not noticeably modify DC seeding of
number of FITC DCs in Apoe/ LNs had matured like the epidermis, LN development, or DC migration. How-
their more numerous wt FITC counterparts. These data ever, by 16 weeks of age, when hypercholesterolemia
indicate that impaired DC migration rather than alter- is marked, there is an evident loss of LCs, and those
ations in DC maturation largely account for the altered that remain in the epidermis appear activated, express-
immune responses in Apoe/ mice. ing MHC II at the plasma membrane instead of retaining
it in a perinuclear deposition that characterizes imma-
ture DCs. Considering the increased number of LCs inPAF-Derived Signals Negatively Regulate
DC Migration the draining LN of Apoe/ mice at 6 weeks of age, the
data suggest that migration of DCs out of the epidermisThe role of PAFAH in restoring DC migration in Apoe/
mice suggests that PAF or PAF-like lipids arising in ath- is stimulated early in the disease before 16 weeks.
Immunity
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Figure 5. Effect of PAFAH-Associated HDL on Immunologic Parameters in Apoe/ Mice
Wt and Apoe/ mice kept on the Western diet for 10 weeks were treated with HDL, Pefabloc-inactivated HDL, or recombinant PAFAH for 7
consecutive days before sensitization and one day after sensitization. (A) CHS and (B) DTH responses were assessed and expressed as ear
swelling. Baseline unchallenged ear thickness was 40  2 m in wt mice and 50  5 m in Apoe/ mice. (C) Expression of costimulatory
molecules on CD11c DCs (steady state) or on CD11cFITC DCs (18h FITC painting) was assessed by flow cytometry in LNs from wt (unfilled
histograms) and Apoe/ mice (filled histograms) at 16 weeks of age and fed a Western diet. Results shown are from one experiment typical
of three conducted. Significant differences from wt controls are designated by *p  0.01.
By 16 weeks, in contrast, migration of DCs to the LN kines like IL-1 and TNF
 (McLachlan et al., 2003) and
chemokines (Palframan et al., 2001) that drain to the LNwas impaired in Apoe/ and in Ldlr/ mice. This defect
was associated with poor priming of CHS and DTH re- and, in “remote control” fashion, promote influx of cells
through high endothelial venules. These mediators pro-sponses, consistent with impaired immunity in athero-
sclerotic mice previously noted by others in a variety of duced by local DCs could also directly attract additional
cells to the skin. Therefore, our data are consistent withchallenges (de Bont et al., 1999; Ludewig et al., 2001;
Netea et al., 1997; Roselaar and Daugherty, 1998; Van the possibility that at earlier points in the disease, DCs
may migrate in response to spontaneous activation andLenten et al., 2002). Poor contact sensitization was not
due to reduced numbers of epidermal DCs, because could prime responses to antigens such that later, when
further capacity for priming is impaired, memory re-treatment with PAFAH nearly fully restored migration,
but increased DC density in the epidermis more slowly. sponses may persist unabated, as memory T cells would
likely traffic to the periphery where DCs are found. In-Moreover, other studies in which LCs are activated by
expression of CD40L in the skin show that a partial loss deed, impaired migration of DCs from the periphery may
even aid in further localizing and exacerbating memoryin LCs does not result in apparent inhibition of migration
after FITC application (Mehling et al., 2001). Despite responses to the periphery, enhancing local tissue reac-
tions.poor migration and consequently poor priming from the
periphery, Apoe/ and Ldlr/ LNs nonetheless become When Apoe/ and Ldlr/ mice are immunologically
challenged, they show impaired priming and reducedmarkedly enlarged, a sign that is often considered a
hallmark of autoimmunity in mice. capacity for clearance of bacteria (de Bont et al., 1999;
Roselaar and Daugherty, 1998), fungi (Netea et al., 1997),Thus, DC migration and immune priming are impaired
even as systemic activation of LNs and skin DCs are and virus (Ludewig et al., 2001). Where time courses
have been conducted, susceptibility to infection doesapparent. In vivo it is unusual to observe epidermal DC
activation even after sensitization. Skin-localized, acti- not occur in younger mice but increases with age and
diet (Ludewig et al., 2001; Moazed et al., 1997), consis-vated DCs might participate in the production of cyto-
Dyslipidemia and DC Migration
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Figure 6. PAFR Expression and Function during DC Migration
(A) Expression of mRNA for PAFR by wt and Pafr/ LCs emigrated from skin explants and by wt and Pafr/ BMDCs was assessed.
(B) After FITC application on skin of wt and Pafr/ mice, FITC CD11c cells in LNs were analyzed. Percent and total number of FITCCD11c
DCs in LNs from wt and Pafr/ mice were determined. Data points are pooled from two experiments.
(C) Migration of DCs after FITC painting was assessed in wt mice treated with the PAFR antagonist CV3988 or ethanol (control solvent) 1 day
before and the day of FITC painting.
(D) Adoptive transfer of BMDCs from WT or Pafr/ CD45.2 mice (donor) was performed in the back skin of wt CD45.1 recipients, or conversely,
BMDCs from wt CD45.1 mice (donor) were transferred to wt and Pafr/ CD45.2 recipients. 2 days after cell transfer, the number of DC that
migrated to brachial LNs was determined. All results are representative of at least two experiments (n  4). Significant differences are
designated by *p  0.05.
(E) Expression of mRNA for PAFR in human LCs was analyzed (left). Calcium flux in human LCs was measured in response to cPAF. Arrow
indicates point of cPAF addition (middle). Culture medium of human skin explants was supplemented with IL-1	, CV3988, its control solvent
(ethanol), or with no additives. Emigration was quantified after 24 hr (right). Data points represent normalized emigration from individual 4
cm2 explants.
tent with the later onset of impaired DC migration. It has of the pathogens in promoting atherosclerosis (Zebrack
and Anderson, 2003; Ludewig et al., 2004) and otherbeen suggested that association of human atherosclero-
sis with Chlamydia pneumoniae and cytomegalovirus autoimmune disorders (Sekigawa et al., 2002). By illus-
trating that DCs poorly prime because they migrate inef-infection may be related to ill management of these
pathogens in the disease (Ludewig et al., 2001) in addi- ficiently to LNs but remain activated in the periphery,
our data can reconcile the current paradox regardingtion to the often discussed possibility of a causative role
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how mediators of innate immunity and signals from Future studies are needed to determine whether PAFAH
might abrogate the scavenger receptor-like recognitionpathogens (Bjorkbacka et al., 2004) or apoptotic debris
(Aprahamian et al., 2004) might lead to exacerbation of between oxidized LDL and chemokines like CCR7 li-
gands and whether this mechanism plays a complemen-local inflammation, autoimmunity, and atherosclerosis
that is coexistent with suppressed immune priming. tary role with negative regulatory signals through PAFR
itself in affecting DC migration in dyslipidemic mice.
Mechanisms of Impaired Migration by PAFAH
Relevance to the Advance of Atherosclerotic PlaquesSubstrates: Mediation through PAFR
Impaired DC emigration from skin parallels impeded mi-and Other Possible Pathways
gratory clearance of monocyte-derived DC-like cellsWe show that HDL, and particularly HDL containing ac-
from atherosclerotic plaques (Llodra et al., 2004). Thus,tive PAFAH, or recombinant PAFAH can reverse im-
in analogy to observations in skin, maintaining the abilitypaired Apoe/ DC migration, and restore immunologic
of DCs, which are abundant in lesions (Bobryshev et al.,priming. These agents have long been known for their
2001), to undergo migratory clearance from lesions mayanti-inflammatory properties (Rong and Fisher, 2000;
diminish plaque size through the clearance of cell massTjoelker and Stafforini, 2000). The protective effect of
and from the removal of potentially activated, cytokine-HDL results in part from its association with PAFAH.
producing cells that may promote further recruitmentIndividuals that bear an inactivating mutation in the
and retention of other cell types. Overexpression of hu-PAFAH gene manifest increased incidence of coronary
man ApoA-I (Rong et al., 2001) or gene therapy ap-heart disease (Yamada et al., 1998). A recent study re-
proaches to promote overexpression of PAFAH (Quarckvealed that an HDL mimetic could reverse the suscepti-
et al., 2001) lead to regression/stabilization of athero-bility of Ldlr/ mice to influenza infection (Van Lenten
sclerotic lesions in mice. These are the same conditionset al., 2002). Our studies agree with the idea that HDL
that reverse impaired DC migration from the skin. Inter-supports a healthy, protective immune response, and
estingly, in Apoe//hApoA-I/ mice, monocyte recruit-suggest that one mechanism by which it does so is
ment to the lesion is not clearly diminished in these micethrough PAFAH activity that maintains normal DC mi-
(Dansky et al., 1999), despite that the fact that overallgration.
lesion size remains lower than in controls. A possibleIt is not yet clear whether the key target of PAFAH in
explanation is that clearance of monocyte-derived DC-these studies is oxidized LDL that can act as a PAF
like cells out of the lesion (Llodra et al., 2004) may bemimetic or PAF itself that would be produced during
promoted by HDL. Thus, the actions of HDL in promotingskin inflammation. That epidermal DCs in Apoe/ mice
DC migration may diminish the advance of atheroscle-exhibited a more-activated phenotype is consistent with
rotic lesions while also generally maintaining homeosta-a role for oxidized LDL in inducing DCs maturation (Al-
sis and normal responsiveness in the DC compart-derman et al., 2002). Since both PAF-like oxidized LDL
ment systemically.and PAF bind to PAFR expressed on skin DCs, they may
each exhibit similar capacity to impair DC migration.
Experimental ProceduresElimination of PAF signaling in Pafr/ mice led to signifi-
cantly increased DC migration even in Apoe/ mice, Mice
and these effects were mediated directly through the Female and male wt mice (CD45.2 and CD45.1) C57BL/6, C57BL/6
deficient for apolipoprotein E (Apoe/), and LDL receptor (Ldlr/)activation of PAFR on DCs. This finding implies that PAF
mice were obtained from Jackson Laboratory. Mice deficient forproduction at inflammatory sites serves as a means to
PAF receptor (Pafr/) and Apoe/ transgenic for human ApoA-Inormally curtail DC migration.
(Apoe//hApoA-I/) fully backcrossed on C57BL/6 backgroundThus, our data are consistent with a model in which
have been previously described (Ishii et al., 1998; Ishii and Shimizu,
PAF-like lipids, which build-up systemically in athero- 2000; Plump et al., 1994). Animals were maintained on a chow diet
sclerotic mice, impair DC migration by signaling through or switched at 6 weeks of age to a high-fat Western diet (21% milk
fat and 0.15% cholesterol; Harlan-Teklad laboratory) for 10 or 28PAFR. However, other mechanisms may also apply. A
additional weeks corresponding to 16 and 34 weeks of age, respec-broad spectrum of chemokines, including the CCR7 li-
tively. All studies were approved by the Institutional Animal Caregands CCL19 and CCL21, can act as soluble scavenger
and Use Committee at Mount Sinai School of Medicine.receptors in vitro (Shimaoka et al., 2004). Binding of
these chemokines to scavenger receptor ligands, such DC Migration Assay
as oxidized LDL, reduce their chemotactic activity by Epicutaneous application of FITC to study DC migration was per-
formed on the ears and/or on three areas of each side of the miceinterfering with chemokine-chemokine receptor binding.
that drain to axillary, brachial, and inguinal LNs as described (Robbi-Interestingly, the inflammatory chemokines CXCL8,
ani et al., 2000). These LNs were recovered 18 hr later, digested inCCL2, and CX3CL1 are not recognized by oxidized LDL.
collagenase D, and pressed through a 70 m cell strainer. The totalThus, the authors suggest, “The lack of OxLDL binding
cell number was evaluated for each sample by using a hemacytome-
activity in CX3CL1 and CCL2 may allow these chemo- ter, and samples were analyzed by flow cytometric analysis by stain-
kines to exhibit chemotactic activity toward targeted ing with PE-conjugated anti-CD11c mAb (Becton Dickinson Biosci-
ences) and with biotinylated anti-I-Ab, CD80, CD86, CD54, or CD40leukocytes in atherosclerotic lesions even in the pres-
mAbs (Becton Dickinson) detected by allophycocyanin-conju-ence of high local concentrations of OxLDL. Conversely,
gated streptavidin.OxLDL may suppress various immune reactions by bind-
ing to various chemokines.” This prediction fits nicely
Quantification of Migration
with our in vivo findings. This model, in which impaired To quantify the number of LCs in the steady state LN, permeabilized
DC migration might result from scavenging of chemo- LN suspensions were stained with langerin mAb (provided by Dr S.
Saeland, Schering Plough) and PE-conjugated anti-rat mAb (Jack-kine activity, is inherently independent of PAFR biology.
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son Immunoresearch). To quantify migration of DCs induced by after sensitization by s.c. injection into the right ear with 30 g of
OVA (adapted from [Itano et al., 2003]). Results are expressed asFITC application, the percentage of FITCCD11c DCs in the total
LN population was assessed by flow cytometry. Expression of data ear swelling as described for CHS. In both CHS and DTH models,
mice were treated with placebo, HDL, pefabloc-treated HDL, oras the percentage of FITC DCs eliminates unrelated variance due
to differences in LN size/cellularity (Supplemental Figure S1). Alter- recombinant PAFAH for 7 consecutive days before and one day
after the sensitization (only during the day of DC migration).natively, the total number of FITCCD11c DCs per LN was calcu-
lated by multiplying the percentage of FITCCD11c cells by the
number of total LN cells. To compare results from different experi- RT-PCR
ments, relative values for individual data points were in some cases Total RNA was isolated from murine LCs that had emigrated from
generated by dividing the value of a data point by the mean of the epidermal sheets of wt and Pafr/ mice ears as described (Schuler
wt control from the same experiment. and Steinman, 1985), from wt or Pafr/ bone marrow-derived DCs,
or from human LCs obtained as described below. cDNA was synthe-
sized from 1 g of total RNA with random hexamer primers andPreparation of Epidermal Sheets and Suspensions
Superscript reverse transcriptase (Life Technologies). PCR amplifi-Epidermal sheets prepared as described (Angeli et al., 2001) were
cations were performed for 29 cycles with the primer pairs: GAPDHstained with anti-I-Ab mAb (BD Biosciences), followed by Cy3-conju-
(453bp), 5-ACCACAGTCCATGCCATCAC-3 (forward) and 5-TCCgated anti-mouse mAb (Jackson Immunoresearch). Deconvolved
ACCACCCTGTTGCTGTA-3 (reverse); mouse PAFR (200 bp), 5-TTGimages showing localization of MHC class II on LCs were acquired
CCTGAGCCATCCTTATT-3 (forward) and 5-CCTCCCACTGTGGATand analyzed by using Openlab and Volocity 2.0 software, respec-
TGTCT-3 (reverse); human PAFR (300bp), 5-ATGACTCCTCCCACtively (Improvision, Inc.). The number of DCs that migrated out of
ATGGAC-3 (forward) and 5-GCAGGGTGATCAAGAAGAGC-3 (re-the skin was enumerated by counting MHC class II-positive cells
verse). Mouse and human CCR7 primers were from R&D Systems.that remained in epidermis 18 hr after FITC application, compared
with the baseline DC density obtained from epidermis to which no
FITC was applied. Five random fields were quantified per sheet. To PAF Receptor Antagonist Administration
measure FITC uptake by epidermal cells, cell suspensions from wt Wt mice were treated intraperitoneally (i.p.) with 20 mg/kg PAFR
and Apoe/ mice were prepared as described (Randolph et al., antagonist CV6988 (Biomol) (Montrucchio et al., 2000), or its solvent
1998b) 18 hr after FITC application on the ears. Cells were stained control (100% ethanol) one day before and the day of FITC applica-
with PE conjugated anti-CD45 mAb (BD Biosciences), and expres- tion. Migration of DCs to the LNs was assayed 18 hr later as de-
sion of FITC on gated CD45 cells was analyzed by flow cytometry. scribed above.
Histology and Immunohistochemistry Bone Marrow-Derived DCs
Skin was snap-frozen in OCT compound and 8 m sections were BMDCs from wt congenic CD45.2, CD45.1, or Pafr/ (CD45.2)
prepared and fixed in 100% acetone for 5 min. For immunohisto- mice were prepared as described (Robbiani et al., 2000) and used
chemistry, sections were blocked with Fc block (BD Biosciences) at day 8 of culture. DCs (0.8  106) from wt or Pafr/ mice were
or 5% goat serum for 10 min. Primary antibodies used included injected in each side of the back skin of congenic CD45.1 recipients.
anti-CD68 (Serotec) and biotinylated anti-CD4 (BD Biosciences). Alternatively, DCs from congenic CD45.1 mice were injected into
Cy3-conjugated streptavidin (Sigma) or Cy3-conjugated donkey wt or Pafr/ recipients. On the day of DC injection and one day after,
anti-rat mAb (Jackson Immunoresearch) was used for detection. recipient mice were painted with 50 l of acetone: dibutylphtalate to
mimic the usual FITC painting assay. 2 days later, migrated DCs in
brachial LNs were analyzed with PE-conjugated anti-CD11c mAbAdministration of Human HDL or Recombinant PAFAH
and biotinylated anti-CD45.1 or CD45.2 mAb (Southern Biotech) andHDL (1.063–1.21g/ml) was isolated by ultracentrifugation (Havel et
detected with allophycocyanin-conjugated streptavidin for analysisal., 1955) from normal plasma or from plasma derived from individu-
by flow cytometry.als who are homozygous deficient for PAFAH. After dialysis against
PBS containing 2 mM EDTA, HDL preparations were sterilized
through a 0.22 m filter and stored under argon at 4C. Protein Human Skin Explants and Calcium Flux
content was determined (BCA kit, Pierce). Mice were treated with Human split-thickness skin explants obtained from organ donors
500 g of human albumin (control) or HDL by daily injection into within 34 hr of death (New York Firefighter’s Skin Bank, Cornell
the tail vein for 7 days. For inactivation of HDL-associated PAFAH, University) were cultured in medium containing 10 M CV3988, its
HDL (2.5 mg/ml) isolated from normal plasma was preincubated for solvent control (100% ethanol), 1 g/ml of IL-1	 (R&D Systems), or
30 min at 37C with 100 M Pefabloc (Roche) and then immediately no additives and analyzed as described previously (Randolph et al.,
dialyzed in PBS-EDTA (Dentan et al., 1996). PAFAH activity was 1998b). Cells were quantified 1 day later.
measured by using a kit from Cayman. In some experiments, mice For calcium flux, emigrated LCs were loaded with FLUO-3 (Molec-
were treated with 0.1 mg/kg of recombinant PAFAH (provided by ular Probe, 5 M) and resuspended to 0.5  106 cell/ml in PBS
ICOS Corporation) or placebo (its solvent control) by daily injection containing 0.03%BSA. After collecting events for several seconds
into the tail vein for 7 days. to establish baseline, 100 nM of carbamyl PAF (Biomol) was added
to the cells and fluorescence was monitored for 2 min by flow cy-
tometry.Measurement of Plasma Lipids
HDL fractions were isolated from mouse plasma samples by density
gradient ultracentrifugation. Total cholesterol and HDL-cholesterol Statistics
were analyzed with commercial kits (Sigma). Statistical comparisons were made by using the Student’s two-
tailed t test. Results are expressed as means SD. All experiments
contained three to four replicates per experimental parameter.Contact Hypersensitivity and Delayed-Type
Hypersensitivity Responses
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